Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer’s disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Roche’s most advanced attempts to treat both diseases have struggled in the clinic. (iStock / Getty Images Plus) When Roche’s gantenerumab failed a pair of phase 3 studies last year, the pharma giant said it would look for “external collaborations and...
Treatment with SLS-005 demonstrated a 46% reduction in tau protein and an 18% reduction in NfL biomarker from baseline values within six months Seelos has been selected to present these data at Neuroscience 2023 to be held on November 11-15, 2023 in Washington, D.C....
GLP-1 receptor agonists, primarily approved for type 2 diabetes and obesity, are emerging as potential treatments for other diseases, including Alzheimer’s. Christian Hölscher of Kariya Pharmaceuticals highlighted the hormone’s diverse effects in the body...
There may be no hotter trend in biopharma right now than GLP-1 receptor agonists. Currently approved to treat type 2 diabetes and obesity, this drug class has also shown potential in other indications, from nonalcoholic fatty liver disease and cardiovascular disease...
